Omada Health, Inc. 8K

Omada Health reported strong Q4 and full-year 2025 growth with a profitable fourth quarter, positive full-year adjusted EBITDA, expanded GLP-1 and AI-enabled offerings, and issued 2026 revenue and adjusted EBITDA guidance.

Omada Health, Inc. filed a Form 8-K to furnish its fourth quarter and full-year 2025 financial results, reporting 58% year-over-year revenue growth in Q4 and 53% for the full year to $260 million, a Q4 net income of $5 million with a significantly reduced full-year net loss of $13 million, positive full-year adjusted EBITDA of $6 million, and cash and cash equivalents of $222 million, alongside operational highlights including 55% member growth to 886,000, expanded GLP-1-related offerings (including the newly announced GLP-1 Flex Care), AI-powered tools OmadaSpark and Meal Map, the launch of Omada for Cholesterol, and providing 2026 guidance for revenue of $312–$322 million and adjusted EBITDA of $7–$15 million.

Filing Facts

CIK

1611115

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-015153

Alert Tier

7